title: Comparative analysis of resuscitation using human serum albumin and crystalloids or 130/0.4 hydroxyethyl starch and crystalloids on skeletal muscle metabolic profile during experimental haemorrhagic shock in swine: A randomised experimental study.
abstract: BACKGROUND
  Protection against acute skeletal muscle metabolic dysfunction and oxidative stress could be a therapeutic target in volume expansion for severely bleeding patients.
  
  
  OBJECTIVE
  This experimental pilot study in swine aims at comparing 130/0.4 hydroxyethyl starch (HES) with 4% albumin along with crystalloid perfusion for first-line volume expansion in haemorrhagic shock with a particular emphasis on oxidative stress and muscular mitochondrial function.
  
  
  METHODS
  Randomised experimental study.
  
  
  METHODS
  Digestive Cancer Research Institute Preclinical Laboratory, Strasbourg University Hospital, France, from February 2012 to June 2013.
  
  
  METHODS
  Twenty large white pigs.
  
  
  METHODS
  Pressure-controlled haemorrhagic shock and volume resuscitation using either 4% human serum albumin or 130/0.4 HES along with crystalloid perfusion were performed in 20 large white pigs.
  
  
  METHODS
  Muscular biopsy of gastrocnemius muscle was performed for metabolomics screening, mitochondrial respiratory chain assessment and electron spin resonance reactive oxygen species production along with arterial and venous reactive oxygen species production at baseline, at the completion of shock, at 90 min and at 180 min after volume expansion.
  
  
  RESULTS
  There was no difference between the two groups in measurements of skeletal muscle superoxide production. In a pooled analysis, there was a statistically significant decrease in gastrocnemius muscle creatine content from baseline to 90 min (P < 0.05) and 180 min (P < 0.05). Muscular lactate content and mitochondrial respiratory chain oxidative capacity remained constant at the respective time points.
  
  
  CONCLUSIONS
  In this pilot experimental study in swine, during pressure-controlled haemorrhagic shock treated with either albumin or 130/0.4 HES in conjunction with crystalloid perfusion, skeletal muscle metabolic profile was unaltered.
  38.2012.01.031.
authors: From the Anesthesia and Intensive Care, Hôpital de Hautepierre, University Hospitals of Strasbourg (EN, JP, PD), EA 3072, Laboratoire de Physiologie, Fédération de Médecine Translationnelle, Strasbourg University (EN, MD, ALC, FS, JP, BG, PD), IHU-Strasbourg, University Institute for Image-Guided Surgery, Strasbourg, France (EN, MD, JP, PD), Department of Anesthesiology, Stony Brook University, Stony Brook, New York, USA (TJG), Biophysics and Nuclear Medicine, Hôpital de Hautepierre, University Hospitals of Strasbourg (F-MM, IJN) and ICube, University of Strasbourg/CNRS UMR 7357, Strasbourg, France (F-MM, IJN).
authors: Eric
authors: E
authors: Noll
authors: Michele
authors: M
authors: Diana
authors: Anne L
authors: AL
authors: Charles
authors: François
authors: F
authors: Singh
authors: Tong J
authors: TJ
authors: Gan
authors: Julien
authors: J
authors: Pottecher
authors: François-Marie
authors: FM
authors: Moussallieh
authors: Izzie J
authors: IJ
authors: Namer
authors: Bernard
authors: B
authors: Geny
authors: Pierre
authors: P
authors: Diemunsch
mesh_terms: D000818:Animals; D000077324:Crystalloid Solutions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage*; D007552:Isotonic Solutions / Q000008:administration & dosage*; D008297:Male; D055432:Metabolomics / Q000379:methods; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000378:metabolism; D010952:Plasma Substitutes / Q000008:administration & dosage; D011897:Random Allocation; D012151:Resuscitation / Q000379:methods*; D000075462:Serum Albumin, Human / Q000008:administration & dosage*; D012771:Shock, Hemorrhagic / Q000188:drug therapy* / Q000378:metabolism; D013552:Swine
chemical_list: D000077324:Crystalloid Solutions; D006895:Hydroxyethyl Starch Derivatives; D007552:Isotonic Solutions; D010952:Plasma Substitutes; D000075462:Serum Albumin, Human